Notably, TrkA is a common off-target for FLT3 and JAK2 inhibitors used in myeloid leukemia treatment, so leukemia patients may benefit from non-intentional TrkA inhibition along with FLT3 or JAK2 (75). The gene discussed is NTRK1; the disease is myeloid leukemia.